Skye Bioscience Treats First Patient in Nimacimab Expansion Study, Aiming for Higher Dosing in Combination with Incretin Therapies.

Skye Bioscience has treated the first patient in a higher-dose expansion study of its CBeyond Phase 2a trial to evaluate safety and pharmacokinetics of nimacimab. The study aims to characterize the drug's exposure-response and inform Phase 2b dose selection for a GLP-1 combination development. The study will test two cohorts of nimacimab monotherapy (400 mg IV and 600 mg IV) compared to placebo, with a 12-week follow-up period. Topline data is expected in Q4 2026.